Discovering and developing innovative therapeutics for CNS disorders

Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.

About Us

Management

Stefan Weber

  - Chief Financial Officer
No Image

Stefan Weber has been the Company’s Chief Financial Officer since April 2005. He holds a master’s degree in business management from Fernuniversitaet Hagen (Diplom-Kaufmann). He has 20 years of industry experience in finance and serves as the chief financial officer of public and private biotechnology companies since 2000. From 1987 to 1999, he worked at the Lohmann group, a worldwide producer of pharmaceutical, medical, technical and consumer products. His final position was head of finance of the Lohmann group. After joining Girindus, a fine chemistry process development and scale-up provider in 1999, he was appointed Chief Financial Officer in 2000. From 2001 to 2005, he was the Chief Financial Officer of Biofrontera, a company active in drug discovery and development. Stefan has been responsible for executing numerous substantial financing transactions, including debt, equity and mezzanine financing as well as national and European grants. He furthermore has been involved in a number of M&A transactions, disinvestments and strategic restructurings. As Chief Financial Officer of Girindus, he managed the company’s initial public offering and post-initial public offering investor relations

<< back